Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Dabrafenib,DBRF1001,2021,USA,MDV,350,62,48,52,27.5,65,85,5,15,35,30,20,45,30,15,10,20,35,30,12,5,3,7,4,10,40,35,DTX,CBDCA+PTX,PTX+CBDCA,AC,2,3,1,25,55,60,15,45,40,60,2
Dabrafenib,DBRF1002,2022,UK,Claim database,420,68,52,48,28.1,58,78,8,12,38,28,22,40,35,17,8,18,37,25,15,7,4,9,5,12,42,38,EC,FEC,CMF,Docetaxel,4,2,1,28,58,63,18,42,40,65,3
Dabrafenib,DBRF1003,2023,Germany,MDV,280,70,55,45,26.8,60,80,6,14,36,29,21,42,32,16,10,19,36,27,14,6,3,8,4,11,41,36,Taxol,CarboTaxol,FEC-T,EC-T,3,1,2,26,56,61,16,44,40,62,2.5
